{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:13:09Z","timestamp":1787775189292,"version":"build-2784847793"},"reference-count":221,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.dld.2022.11.015","type":"journal-article","created":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T23:17:56Z","timestamp":1670800676000},"page":"187-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["Italian guidelines for the management of irritable bowel syndrome"],"prefix":"10.1016","volume":"55","author":[{"given":"Giovanni","family":"Barbara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Cremon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Bellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Corsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Nardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Falangone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Fuccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Iovino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Sarnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo Vincenzo","family":"Savarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Stanghellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Staiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Stasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Tosetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Turco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Ubaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco Maurizio","family":"Zagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Zenzeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Marasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2022.11.015_bib0001","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Lacy","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0002","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0003","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/apt.12942","article-title":"Conducting multinational, cross-cultural research in the functional gastrointestinal disorders: issues and recommendations. A Rome Foundation working team report","volume":"40","author":"Sperber","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0004","first-page":"2986","article-title":"Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis","volume":"23","author":"Flacco","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.dld.2022.11.015_bib0005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cgh.2011.08.015","article-title":"Diagnosis, comorbidities, and management of irritable bowel syndrome in patients in a large health maintenance organization","volume":"10","author":"Ladabaum","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"109 Suppl","key":"10.1016\/j.dld.2022.11.015_bib0006","article-title":"American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation","author":"Ford","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0007","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1056\/NEJMra1607547","article-title":"Irritable Bowel Syndrome","volume":"376","author":"Ford","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2022.11.015_bib0008","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ajg.2016.308","article-title":"Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation","volume":"111","author":"Sood","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2012.12.038","article-title":"A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome","volume":"11","author":"Begtrup","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.11.015_bib0010","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-015-0398-8","article-title":"Comparison of medical costs generated by IBS patients in primary and secondary care in the Netherlands","volume":"15","author":"Flik","year":"2015","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0011","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/j.1365-2036.2004.02250.x","article-title":"Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications","volume":"20","author":"Vandvik","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0012","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jpsychores.2013.05.008","article-title":"An international Delphi study to assess the need for multiaxial criteria in diagnosis and management of functional gastrointestinal disorders","volume":"75","author":"Austin","year":"2013","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.dld.2022.11.015_bib0013","first-page":"1147","article-title":"Type, Rather Than Number, of Mental and Physical Comorbidities Increases the Severity of Symptoms in Patients With Irritable Bowel Syndrome","volume":"11","author":"Lackner","year":"2013","journal-title":"YJCGH"},{"key":"10.1016\/j.dld.2022.11.015_bib0014","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nrgastro.2013.259","article-title":"Mechanisms and efficacy of dietary FODMAP restriction in IBS","volume":"11","author":"Staudacher","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.11.015_bib0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5056\/jnm.2012.18.1.13","article-title":"Psychological co-morbidity in functional gastrointestinal disorders: Epidemiology, mechanisms and management","volume":"18","author":"Wu","year":"2012","journal-title":"J Neurogastroenterol Motil"},{"key":"10.1016\/j.dld.2022.11.015_bib0016","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00406-014-0502-z","article-title":"Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis","volume":"264","author":"Fond","year":"2014","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.dld.2022.11.015_bib0017","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1053\/j.gastro.2016.02.027","article-title":"Biopsychosocial aspects of functional gastrointestinal disorders: How central and environmental processes contribute to the development and expression of functional gastrointestinal disorders","volume":"150","author":"Van Oudenhove","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0018","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/apt.15325","article-title":"Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome","volume":"50","author":"Zamani","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0019","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jpsychores.2013.03.004","article-title":"Which psychological factors exacerbate irritable bowel syndrome? Development of a comprehensive model","volume":"74","author":"Van Tilburg","year":"2013","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.dld.2022.11.015_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpsychores.2019.109821","article-title":"Effects of a comprehensive self-management intervention on extraintestinal symptoms among patients with IBS","volume":"126","author":"Kamp","year":"2019","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.dld.2022.11.015_bib0021","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjhp.12250","article-title":"The journey between brain and gut: A systematic review of psychological mechanisms of treatment effect in irritable bowel syndrome","volume":"22","author":"Windgassen","year":"2017","journal-title":"Br J Health Psychol"},{"key":"10.1016\/j.dld.2022.11.015_bib0022","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/ajg.2010.47","article-title":"Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts","volume":"105","author":"Spiegel","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0023","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.dld.2005.06.011","article-title":"The general practitioner's approach to irritable bowel syndrome: from intention to practice","volume":"37","author":"Bellini","year":"2005","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2022.11.015_bib0024","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.dld.2018.10.006","article-title":"IBS clinical management in Italy: The AIGO survey","volume":"51","author":"Soncini","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2022.11.015_bib0025","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14004","article-title":"A positive diagnostic strategy is safe and saves endoscopies in patients with irritable bowel syndrome: A five-year follow-up of a randomized controlled trial","volume":"33","author":"Engsbro","year":"2021","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.dld.2022.11.015_bib0026","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/j.1572-0241.2004.30176.x","article-title":"The role of pelvic floor dysfunction and slow colonic transit in adolescents with refractory constipation","volume":"99","author":"Chitkara","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0027","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41395-018-0006-y","article-title":"Rectal Exam: Yes, it can and should be done in a busy practice!","volume":"113","author":"Rao","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0028","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/DCR.0000000000001250","article-title":"The Contributions of Internal Intussusception, Irritable Bowel Syndrome, and Pelvic Floor Dyssynergia to Obstructed Defecation Syndrome","volume":"62","author":"Cavallaro","year":"2019","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.dld.2022.11.015_bib0029","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ajg.2015.153","article-title":"The diagnostic value of a digital rectal examination compared with high-resolution anorectal manometry in patients with chronic constipation and fecal incontinence","volume":"110","author":"Soh","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0030","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.cgh.2010.06.031","article-title":"Digital rectal examination is a useful tool for identifying patients with dyssynergia","volume":"8","author":"Tantiphlachiva","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.11.015_bib0031","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1053\/j.gastro.2016.02.009","article-title":"Functional Anorectal Disorders","volume":"150","author":"Rao","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0032","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-016-0556-7","article-title":"Chronic constipation diagnosis and treatment evaluation: the \u201cCHRO.CO.DI.T.E.\u201d study","volume":"17","author":"Bellini","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0033","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10151-018-1921-z","article-title":"Pelvic floor rehabilitation for defecation disorders","volume":"23","author":"Bocchini","year":"2019","journal-title":"Tech Coloproctol"},{"key":"10.1016\/j.dld.2022.11.015_bib0034","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/MCG.0b013e31820c6001","article-title":"Outcome of biofeedback therapy in dyssynergic defecation patients with and without irritable bowel syndrome","volume":"45","author":"Patcharatrakul","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0035","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14264","article-title":"Pelvic floor biofeedback is an effective treatment for severe bloating in disorders of gut-brain interaction with outlet dysfunction","volume":"34","author":"Iovino","year":"2022","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.dld.2022.11.015_bib0036","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0140-6736(17)31796-8","article-title":"Coeliac disease","volume":"391","author":"Lebwohl","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.dld.2022.11.015_bib0037","first-page":"13","article-title":"Food Allergy and Intolerance: A Narrative Review on Nutritional Concerns","author":"Gargano","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.dld.2022.11.015_bib0038","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cgh.2017.06.037","article-title":"Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis","volume":"16","author":"Singh","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.11.015_bib0039","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.cgh.2012.11.033","article-title":"Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: a meta-analysis","volume":"11","author":"Sainsbury","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.11.015_bib0040","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/gut.30.3.333","article-title":"Malignancy in coeliac disease\u2013effect of a gluten free diet","volume":"30","author":"Holmes","year":"1989","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.11.015_bib0041","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/ajg.2016.466","article-title":"Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis","volume":"112","author":"Irvine","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0042","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/MEG.0000000000001022","article-title":"Celiac disease is uncommon in irritable bowel syndrome in the USA","volume":"30","author":"Almazar","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.11.015_bib0043","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1373\/clinchem.2008.103606","article-title":"Celiac disease and IgA deficiency: complications of serological testing approaches encountered in the clinic","volume":"54","author":"McGowan","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.dld.2022.11.015_bib0044","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1053\/j.gastro.2004.03.012","article-title":"Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis","volume":"126","author":"Spiegel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0045","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.gtc.2005.02.007","article-title":"Is irritable bowel syndrome a low-grade inflammatory bowel disease?","volume":"34","author":"Bercik","year":"2005","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.dld.2022.11.015_bib0046","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1111\/j.1572-0241.2002.07027.x","article-title":"The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review","volume":"97","author":"Cash","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106478","article-title":"The incidence of other gastroenterological disease following diagnosis of irritable bowel syndrome in the UK: a cohort study","volume":"9","author":"Canavan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2022.11.015_bib0048","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1572-0241.2007.01556.x","article-title":"Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices","volume":"103","author":"Langhorst","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0049","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ibd.20275","article-title":"Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies","volume":"14","author":"Schoepfer","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2022.11.015_bib0050","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1515\/CCLM.2008.361","article-title":"Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome","volume":"46","author":"Otten","year":"2008","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.dld.2022.11.015_bib0051","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1053\/j.gastro.2019.06.014","article-title":"AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D)","volume":"157","author":"Carrasco-Labra","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0052","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-044177","article-title":"Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the IMRD-UK data","volume":"11","author":"Freeman","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.dld.2022.11.015_bib0053","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/bmj.c3369","article-title":"Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis","volume":"341","author":"van Rheenen","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.dld.2022.11.015_bib0054","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7754\/Clin.Lab.2020.191029","article-title":"Automated Fecal Biomarker Profiling - a Convenient Procedure to Support Diagnosis for Patients with Inflammatory Bowel Diseases","volume":"66","author":"Kraemer","year":"2020","journal-title":"Clin Lab"},{"key":"10.1016\/j.dld.2022.11.015_bib0055","article-title":"Analytical and clinical performance of the fully-automated LIAISONXL calprotectin immunoassay from DiaSorin in IBD patients","volume":"21","author":"Vicente-Steijn","year":"2020","journal-title":"Pract Lab Med"},{"key":"10.1016\/j.dld.2022.11.015_bib0056","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ajg.2015.6","article-title":"A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS","volume":"110","author":"Menees","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0057","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1053\/gast.2002.34755","article-title":"Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease","volume":"123","author":"Tibble","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0058","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2018.07.011","article-title":"Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome","volume":"156","author":"Barbara","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0059","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1053\/j.gastro.2016.12.039","article-title":"Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis","volume":"152","author":"Klem","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0060","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1572-0241.1999.01077.x","article-title":"Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria","volume":"94","author":"Hamm","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0061","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1128\/JCM.02877-13","article-title":"Detection of intestinal protozoa in the clinical laboratory","volume":"52","author":"McHardy","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.dld.2022.11.015_bib0062","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","article-title":"ACG Clinical Guideline: Management of Irritable Bowel Syndrome","volume":"116","author":"Lacy","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.dld.2022.11.015_bib0063","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1111\/j.1572-0241.1999.01437.x","article-title":"Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome","volume":"94","author":"Vanner","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0064","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cgh.2020.08.062","article-title":"Diagnostic Yield of Colonoscopy in Patients With Symptoms Compatible With Rome IV Functional Bowel Disorders","volume":"20","author":"Asghar","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Jan-Feb","key":"10.1016\/j.dld.2022.11.015_bib0065","doi-asserted-by":"crossref","first-page":"56","DOI":"10.37080\/nmj.19","article-title":"Prevalence of organic colonic lesions by colonoscopy in patients fulfilling ROME IV criteria of irritable bowel syndrome","author":"Paudel","year":"2018","journal-title":"JNMA J Nepal Med Assoc"},{"key":"10.1016\/j.dld.2022.11.015_bib0066","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3109\/00365521.2015.1007079","article-title":"Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey","volume":"50","author":"Patel","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0067","first-page":"8837","article-title":"Irritable bowel syndrome and food interaction","volume":"20","author":"Cuomo","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0068","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41395-018-0084-x","article-title":"American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome","volume":"113","author":"Ford","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0069","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1136\/gut.2003.037697","article-title":"Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial","volume":"53","author":"Atkinson","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.11.015_bib0070","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2017-000164","article-title":"Efficacy of individualised diets in patients with irritable bowel syndrome: a randomised controlled trial","volume":"4","author":"Ali","year":"2017","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0071","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jcag\/gwy071","article-title":"Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS)","volume":"2","author":"Moayyedi","year":"2019","journal-title":"J Can Assoc Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0072","doi-asserted-by":"crossref","DOI":"10.15403\/jgld-3581","article-title":"Romanian Guidelines for Nonpharmacological Therapy of IBS","volume":"30","author":"Dumitrascu","year":"2021","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.dld.2022.11.015_bib0073","first-page":"125","article-title":"Food allergy","author":"Sicherer","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.dld.2022.11.015_bib0074","first-page":"126","article-title":"National prevalence and risk factors for food allergy and relationship to asthma: results from the National Health and Nutrition Examination Survey 2005-2006","author":"Liu","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.dld.2022.11.015_bib0075","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.jaci.2005.05.047","article-title":"Prevalence of sensitization to food allergens, reported adverse reaction to foods, food avoidance, and food hypersensitivity among teenagers","volume":"116","author":"Pereira","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.dld.2022.11.015_bib0076","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jaci.2007.05.026","article-title":"The prevalence of food allergy: a meta-analysis","volume":"120","author":"Rona","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.dld.2022.11.015_bib0077","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/iid3.320","article-title":"Prevalence of IgE-mediated sensitization in patients with suspected food allergic reactions in Jordan","volume":"8","author":"Abu-Dayyeh","year":"2020","journal-title":"Immunity, Inflamm Dis"},{"key":"10.1016\/j.dld.2022.11.015_bib0078","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.12984","article-title":"Review article: the diagnosis and management of food allergy and food intolerances","volume":"41","author":"Turnbull","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0079","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.jaci.2005.02.038","article-title":"Diagnosing peanut allergy with skin prick and specific IgE testing","volume":"115","author":"Roberts","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.dld.2022.11.015_bib0080","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41586-020-03118-2","article-title":"Local immune response to food antigens drives meal-induced abdominal pain","volume":"590","author":"Aguilera-Lizarraga","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.dld.2022.11.015_bib0081","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1365-2036.2007.03328.x","article-title":"Irritable bowel syndrome: patients\u2019 attitudes, concerns and level of knowledge","volume":"25","author":"Lacy","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0082","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(94)90234-8","article-title":"A population study of food intolerance","volume":"343","author":"Young","year":"1994","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.dld.2022.11.015_bib0083","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.ejcn.1602367","article-title":"Perceived food intolerance in subjects with irritable bowel syndrome\u2013 etiology, prevalence and consequences","volume":"60","author":"Monsbakken","year":"2006","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.dld.2022.11.015_bib0084","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/ajg.2013.105","article-title":"Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life","volume":"108","author":"B\u00f6hn","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0085","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.3748\/wjg.v20.i22.6759","article-title":"Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine","volume":"20","author":"Saha","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0086","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1053\/j.gastro.2020.06.090","article-title":"AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review","volume":"159","author":"Quigley","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0087","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MEG.0000000000000122","article-title":"Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture","volume":"26","author":"Ghoshal","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.11.015_bib0088","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1007\/s10620-020-06484-z","article-title":"Diagnosing Small Intestinal Bacterial Overgrowth: A Comparison of Lactulose Breath Tests to Small Bowel Aspirates","volume":"66","author":"Cangemi","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2022.11.015_bib0089","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/gut.2009.205476","article-title":"Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS","volume":"60","author":"Yu","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.11.015_bib0090","doi-asserted-by":"crossref","first-page":"190","DOI":"10.14309\/ajg.0000000000000504","article-title":"Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies","volume":"115","author":"Shah","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0091","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/jgh.14938","article-title":"A meta-analysis on small intestinal bacterial overgrowth in patients with different subtypes of irritable bowel syndrome","volume":"35","author":"Ghoshal","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.11.015_bib0092","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41575-020-0270-3","article-title":"Evidence-based and mechanistic insights into exclusion diets for IBS","volume":"17","author":"Moayyedi","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.11.015_bib0093","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/jhn.12385","article-title":"British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update)","volume":"29","author":"McKenzie","year":"2016","journal-title":"J Hum Nutr Diet"},{"key":"10.1016\/j.dld.2022.11.015_bib0094","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1053\/j.gastro.2015.07.054","article-title":"Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial","volume":"149","author":"B\u00f6hn","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0095","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/ajg.2016.434","article-title":"A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D","volume":"111","author":"Eswaran","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0096","first-page":"11","article-title":"Effect of Structural Individual Low-FODMAP Dietary Advice vs. Brief Advice on a Commonly Recommended Diet on IBS Symptoms and Intestinal Gas Production","author":"Patcharatrakul","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.dld.2022.11.015_bib0097","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ajcn\/nqab005","article-title":"Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet compared with traditional dietary advice for diarrhea-predominant irritable bowel syndrome: a parallel-group, randomized controlled trial with analysis of clinical and micr","volume":"113","author":"Zhang","year":"2021","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.dld.2022.11.015_bib0098","doi-asserted-by":"crossref","DOI":"10.3390\/nu12010148","article-title":"Low FODMAP Diet: Evidence, Doubts, and Hopes","volume":"12","author":"Bellini","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.dld.2022.11.015_bib0099","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu13020575","article-title":"Impact of Diet on Symptoms of the Irritable Bowel Syndrome","volume":"13","author":"Spiller","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.dld.2022.11.015_bib0100","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.12969","article-title":"Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome","volume":"29","author":"Hustoft","year":"2017","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.dld.2022.11.015_bib0101","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-277X.2011.01162.x","article-title":"Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome","volume":"24","author":"Staudacher","year":"2011","journal-title":"J Hum Nutr Diet"},{"key":"10.1016\/j.dld.2022.11.015_bib0102","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.gastro.2013.09.046","article-title":"A diet low in FODMAPs reduces symptoms of irritable bowel syndrome","volume":"146","author":"Halmos","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0103","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.3748\/wjg.v23.i25.4632","article-title":"Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs","volume":"23","author":"Harvie","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0104","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1053\/j.gastro.2017.06.010","article-title":"A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial","volume":"153","author":"Staudacher","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0105","doi-asserted-by":"crossref","first-page":"906","DOI":"10.14309\/ajg.0000000000000641","article-title":"\u03b2-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria","volume":"115","author":"Wilson","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0106","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/gutjnl-2015-311339","article-title":"FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial","volume":"66","author":"McIntosh","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.11.015_bib0107","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1136\/gutjnl-2021-324598","article-title":"British Society of Gastroenterology guidelines on the management of irritable bowel syndrome","volume":"70","author":"Vasant","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.11.015_bib0108","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1007\/s00394-021-02620-1","article-title":"Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis","volume":"60","author":"van Lanen","year":"2021","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.dld.2022.11.015_bib0109","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41395-018-0195-4","article-title":"A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome","volume":"113","author":"Dionne","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0110","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13154","article-title":"Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome","volume":"30","author":"O'Keeffe","year":"2018","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.dld.2022.11.015_bib0111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu12082360","article-title":"A Low-FODMAP Diet for Irritable Bowel Syndrome: Some Answers to the Doubts from a Long-Term Follow-Up","volume":"12","author":"Bellini","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.dld.2022.11.015_bib0112","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.dld.2021.05.004","article-title":"The low FODMAP diet for IBS; A multicentre UK study assessing long term follow up","volume":"53","author":"Rej","year":"2021","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2022.11.015_bib0113","doi-asserted-by":"crossref","DOI":"10.1186\/s13052-019-0606-1","article-title":"Efficacy of the gluten free diet in the management of functional gastrointestinal disorders: a systematic review on behalf of the Italian Society of Paediatrics","volume":"45","author":"Scarpato","year":"2019","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.dld.2022.11.015_bib0114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu12113368","article-title":"Low Fermentable Oligo- Di- and Mono-Saccharides and Polyols (FODMAPs) or Gluten Free Diet: What Is Best for Irritable Bowel Syndrome?","volume":"12","author":"Bellini","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.dld.2022.11.015_bib0115","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/ajg.2010.487","article-title":"Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial","volume":"106","author":"Biesiekierski","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0116","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.3390\/nu7064542","article-title":"Non-Celiac Gluten Sensitivity Has Narrowed the Spectrum of Irritable Bowel Syndrome: A Double-Blind Randomized Placebo-Controlled Trial","volume":"7","author":"Shahbazkhani","year":"2015","journal-title":"Nutrients"},{"key":"10.1016\/j.dld.2022.11.015_bib0117","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0140-6736(18)31809-9","article-title":"Te Morenga L. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses","volume":"393","author":"Reynolds","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.dld.2022.11.015_bib0118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu12103209","article-title":"The Health Benefits of Dietary Fibre","volume":"12","author":"Barber","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.dld.2022.11.015_bib0119","first-page":"11","article-title":"The Dietary Management of Patients with Irritable Bowel Syndrome: A Narrative Review of the Existing and Emerging Evidence","author":"Algera","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.dld.2022.11.015_bib0120","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/flgastro-2019-101298","article-title":"Best management of irritable bowel syndrome","volume":"12","author":"Black","year":"2020","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0121","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(94)91055-3","article-title":"Bran and irritable bowel syndrome: time for reappraisal","volume":"344","author":"Francis","year":"1994","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.dld.2022.11.015_bib0122","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/apt.13167","article-title":"Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome","volume":"41","author":"Rao","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0123","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","article-title":"Expert consensus document: The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic","volume":"11","author":"Hill","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.11.015_bib0124","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coph.2018.08.010","article-title":"Pre- and probiotic overview","volume":"43","author":"Cremon","year":"2018","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.dld.2022.11.015_bib0125","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/apt.15001","article-title":"Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome","volume":"48","author":"Ford","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0126","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S2468-1253(20)30056-X","article-title":"Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial","volume":"5","author":"Andresen","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.11.015_bib0127","doi-asserted-by":"crossref","DOI":"10.3390\/nu12041159","article-title":"Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study","volume":"12","author":"Lewis","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.dld.2022.11.015_bib0128","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.dld.2019.12.009","article-title":"A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial","volume":"52","author":"Sadrin","year":"2020","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2022.11.015_bib0129","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1007\/s00394-020-02437-4","article-title":"Adjunctive treatment with probiotics partially alleviates symptoms and reduces inflammation in patients with irritable bowel syndrome","volume":"60","author":"Xu","year":"2021","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.dld.2022.11.015_bib0130","doi-asserted-by":"crossref","first-page":"e23641","DOI":"10.1097\/MD.0000000000023641","article-title":"Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant]","volume":"100","author":"Gupta","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.dld.2022.11.015_bib0131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu13030756","article-title":"The effectiveness and safety of multi-strain probiotic preparation in patients with diarrhea-predominant irritable bowel syndrome: A randomized controlled study","volume":"13","author":"Skrzyd\u0142o-Radoma\u0144ska","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.dld.2022.11.015_bib0132","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-016-0457-9","article-title":"Comparison of the effectiveness of polyethylene glycol with and without electrolytes in constipation: a systematic review and network meta-analysis","volume":"16","author":"Katelaris","year":"2016","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0133","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/gut.2010.227132","article-title":"Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis","volume":"60","author":"Ford","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.11.015_bib0134","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1572-0241.2000.01765.x","article-title":"A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative","volume":"95","author":"DiPalma","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0135","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/j.1572-0241.2007.01199.x","article-title":"A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation","volume":"102","author":"DiPalma","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0136","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2036.2003.01390.x","article-title":"Comparison of efficacy and safety of two doses of two different polyethylene glycol-based laxatives in the treatment of constipation","volume":"17","author":"Chaussade","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0137","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12603-016-0762-6","article-title":"Tolerance and Long-Term Efficacy of Polyethylene Glycol 4000 (Forlax\u00ae) Compared to Lactulose in Elderly Patients with Chronic Constipation","volume":"21","author":"Chassagne","year":"2017","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/j.dld.2022.11.015_bib0138","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1053\/j.gastro.2014.09.002","article-title":"American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome","volume":"147","author":"Chang","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0139","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2036.2008.03629.x","article-title":"Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation","volume":"27","author":"Johanson","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0140","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2036.2008.03881.x","article-title":"Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome\u2013results of two randomized, placebo-controlled studies","volume":"29","author":"Drossman","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0141","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/apt.13807","article-title":"Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation","volume":"44","author":"Chang","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0142","first-page":"139","article-title":"Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation","author":"Johnston","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0143","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/ajg.2012.254","article-title":"Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety","volume":"107","author":"Chey","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0144","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/ajg.2012.255","article-title":"A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation","volume":"107","author":"Rao","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/apt.12123","article-title":"Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints","volume":"37","author":"Quigley","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0146","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ajg.2017.495","article-title":"Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis","volume":"113","author":"Shah","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0147","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1053\/j.gastro.2018.08.021","article-title":"Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis","volume":"155","author":"Black","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0148","doi-asserted-by":"crossref","first-page":"281","DOI":"10.14309\/ajg.0000000000000516","article-title":"Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)","volume":"115","author":"Chey","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0149","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.14309\/ajg.0000000000001056","article-title":"Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)","volume":"116","author":"Chey","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0150","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1517\/17425255.2012.719497","article-title":"Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation","volume":"8","author":"Tack","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.dld.2022.11.015_bib0151","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1365-2036.2001.00925.x","article-title":"Review article: tegaserod","volume":"15","author":"Camilleri","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0152","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/ajg.2009.223","article-title":"Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis","volume":"104","author":"Ford","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0153","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2174\/1871523018666190911121306","article-title":"Tegaserod for the Treatment of Irritable Bowel Syndrome","volume":"19","author":"Madia","year":"2020","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"key":"10.1016\/j.dld.2022.11.015_bib0154","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S2468-1253(19)30246-8","article-title":"Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis","volume":"4","author":"Luthra","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.11.015_bib0155","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.14309\/ajg.0000000000000696","article-title":"The Role of Bile Acids in Chronic Diarrhea","volume":"115","author":"Camilleri","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0156","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/apt.13065","article-title":"Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome","volume":"41","author":"Camilleri","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0157","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/archinte.1972.03650040121011","article-title":"Bile acid malabsorption caused by ileal resection","volume":"130","author":"Hofmann","year":"1972","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.dld.2022.11.015_bib0158","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/gut.28.8.970","article-title":"75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit","volume":"28","author":"Sciarretta","year":"1987","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.11.015_bib0159","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/gut.32.9.1004","article-title":"Idiopathic bile acid malabsorption\u2013a review of clinical presentation, diagnosis, and response to treatment","volume":"32","author":"Williams","year":"1991","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.11.015_bib0160","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/gutjnl-2013-305965","article-title":"Increased colonic bile acid exposure: A relevant factor for symptoms and treatment in IBS","volume":"64","author":"Bajor","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.11.015_bib0161","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2009.10.020","article-title":"Effects of Chenodeoxycholate and a Bile Acid Sequestrant, Colesevelam, on Intestinal Transit and Bowel Function","volume":"8","author":"Odunsi-Shiyanbade","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.11.015_bib0162","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.phrs.2014.05.001","article-title":"Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers","volume":"85","author":"Blandizzi","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.dld.2022.11.015_bib0163","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10620-007-9839-8","article-title":"Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS","volume":"53","author":"Yang","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2022.11.015_bib0164","doi-asserted-by":"crossref","first-page":"557","DOI":"10.7326\/0003-4819-145-8-200610170-00004","article-title":"The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial","volume":"145","author":"Pimentel","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2022.11.015_bib0165","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s10620-011-1728-5","article-title":"Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects","volume":"56","author":"Pimentel","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2022.11.015_bib0166","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2022.11.015_bib0167","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1053\/j.gastro.2016.08.003","article-title":"Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome","volume":"151","author":"Lembo","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0168","doi-asserted-by":"crossref","first-page":"e00144","DOI":"10.14309\/ctg.0000000000000144","article-title":"Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea","volume":"11","author":"Lembo","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0169","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.14309\/ajg.0000000000000444","article-title":"Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea","volume":"114","author":"Rezaie","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0170","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.amjmed.2011.08.026","article-title":"Evaluation of harm in the pharmacotherapy of irritable bowel syndrome","volume":"125","author":"Shah","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.dld.2022.11.015_bib0171","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/apt.12735","article-title":"Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials","volume":"39","author":"Schoenfeld","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0172","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/gutjnl-2018-318160","article-title":"Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis","volume":"69","author":"Black","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.11.015_bib0173","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s10620-017-4598-7","article-title":"Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity","volume":"62","author":"Pimentel","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2022.11.015_bib0174","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1007\/s10620-014-3157-8","article-title":"Antibiotic treatment of constipation-predominant irritable bowel syndrome","volume":"59","author":"Pimentel","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2022.11.015_bib0175","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.clinthera.2008.05.002","article-title":"Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials","volume":"30","author":"Rahimi","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0176","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cgh.2007.12.015","article-title":"Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Andresen","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.11.015_bib0177","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1572-0241.2004.04097.x","article-title":"Occurrence of colon ischemia in relation to irritable bowel syndrome","volume":"99","author":"Cole","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0178","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1572-0241.2006.00459.x","article-title":"Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data","volume":"101","author":"Chang","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0179","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-017-0734-2","article-title":"Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Qi","year":"2018","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0180","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gutjnl-2013-305989","article-title":"A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea","volume":"63","author":"Garsed","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.11.015_bib0181","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.14309\/ajg.0000000000000727","article-title":"Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial","volume":"115","author":"Plasse","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0182","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/apt.15420","article-title":"Abnormalities of mucosal serotonin metabolism and 5-HT 3 receptor subunit 3C polymorphism in irritable bowel syndrome with diarrhoea predict responsiveness to ondansetron","volume":"50","author":"Gunn","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0183","doi-asserted-by":"crossref","first-page":"150","DOI":"10.7861\/clinmed.2020-1046","article-title":"Loperamide: an emerging drug of abuse and cause of prolonged QTc","volume":"21","author":"Whittaker","year":"2021","journal-title":"Clin Med"},{"key":"10.1016\/j.dld.2022.11.015_bib0184","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF01296258","article-title":"Role of loperamide and placebo in management of irritable bowel syndrome (IBS)","volume":"29","author":"Cann","year":"1984","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2022.11.015_bib0185","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for Irritable Bowel Syndrome with Diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2022.11.015_bib0186","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/ajg.2016.542","article-title":"Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea","volume":"112","author":"Cash","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0187","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1136\/gutjnl-2013-305994","article-title":"Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome","volume":"63","author":"Jalanka-Tuovinen","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.11.015_bib0188","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2016.09.049","article-title":"Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome","volume":"152","author":"Tap","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0189","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.15330","article-title":"Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome","volume":"50","author":"Ianiro","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0190","doi-asserted-by":"crossref","unstructured":"Myneedu K., Deoker A., Schmulson M.J., Bashashati M. Fecal microbiota transplantation in irritable bowel syndrome: A systematic review and meta-analysis n.d. doi:10.1177\/2050640619866990.","DOI":"10.1177\/2050640619866990"},{"key":"10.1016\/j.dld.2022.11.015_bib0191","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/apt.15740","article-title":"Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome","volume":"51","author":"Lahtinen","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0192","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/gutjnl-2019-319630","article-title":"Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study","volume":"69","author":"El-Salhy","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.11.015_bib0193","doi-asserted-by":"crossref","DOI":"10.3390\/jcm6110101","article-title":"Pharmacotherapy for Irritable Bowel Syndrome","volume":"6","author":"Camilleri","year":"2017","journal-title":"J Clin Med"},{"key":"10.1016\/j.dld.2022.11.015_bib0194","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.3748\/wjg.v20.i20.6031","article-title":"Role of antispasmodics in the treatment of irritable bowel syndrome","volume":"20","author":"Annah\u00e1zi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0195","article-title":"Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome","volume":"2011","author":"Ruepert","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.dld.2022.11.015_bib0196","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/1756283X16681708","article-title":"Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis","volume":"10","author":"Clav\u00e9","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0197","doi-asserted-by":"crossref","DOI":"10.1186\/s12906-018-2409-0","article-title":"The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data","volume":"19","author":"Alammar","year":"2019","journal-title":"BMC Complement Altern Med"},{"key":"10.1016\/j.dld.2022.11.015_bib0198","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.gastro.2019.08.026","article-title":"Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome","volume":"158","author":"Weerts","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0199","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2017.11.279","article-title":"Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report","volume":"154","author":"Drossman","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0200","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14080","article-title":"Deconstructing stigma as a barrier to treating DGBI: Lessons for clinicians","volume":"33","author":"Feingold","year":"2021","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.dld.2022.11.015_bib0201","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41395-018-0222-5","article-title":"Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis","volume":"114","author":"Ford","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.11.015_bib0202","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/apt.15077","article-title":"Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome","volume":"49","author":"Saito","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0203","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/apt.13958","article-title":"Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome","volume":"45","author":"Cremon","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.11.015_bib0204","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1053\/j.gastro.2011.07.036","article-title":"Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome","volume":"141","author":"Wong","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.11.015_bib0205","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2982.2011.01874.x","article-title":"Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea","volume":"24","author":"Wong","year":"2012","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.dld.2022.11.015_bib0206","article-title":"Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of Irritable Bowel Syndrome Patients: A Placebo-Controlled Crossover Exploratory Intervention Study with Symptom-Driven Dosing","author":"van Orten-Luiten","year":"2021","journal-title":"Cannabis Cannabinoid Res"},{"issue":"11","key":"10.1016\/j.dld.2022.11.015_bib0207","first-page":"705","article-title":"Complementary and alternative medicine modalities for the treatment of irritable bowel syndrome: Facts or myths?","volume":"6","author":"Wu","year":"2010","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.11.015_bib0208","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/2050640613499567","article-title":"A survey of pharmacological and nonpharmacological treatment of functional gastrointestinal disorders","volume":"1","author":"Lahner","year":"2013","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.dld.2022.11.015_bib0209","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11655-016-2596-9","article-title":"Therapeutic Effect of Chang'an I Recipe (I) on Irritable Bowel Syndrome with Diarrhea: A Multicenter Randomized Double-Blind Placebo-Controlled Clinical Trial","volume":"24","author":"dong","year":"2018","journal-title":"Chin J Integr Med"},{"key":"10.1016\/j.dld.2022.11.015_bib0210","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.cgh.2020.09.035","article-title":"Potential Benefit With Complementary and Alternative Medicine in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis","volume":"19","author":"Billings","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.11.015_bib0211","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctim.2019.102233","article-title":"Western herbal medicines in the treatment of irritable bowel syndrome: A systematic review and meta-analysis","volume":"48","author":"Hawrelak","year":"2020","journal-title":"Complement Ther Med"},{"key":"10.1016\/j.dld.2022.11.015_bib0212","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/gutjnl-2020-321191","article-title":"Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis","volume":"69","author":"Black","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.11.015_bib0213","first-page":"1613","article-title":"Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): A multicentre randomised trial","volume":"68","author":"Everitt","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.11.015_bib0214","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2468-1253(19)30243-2","article-title":"Cognitive behavioural therapy for irritable bowel syndrome: 24-month follow-up of participants in the ACTIB randomised trial","volume":"4","author":"Everitt","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.11.015_bib0215","doi-asserted-by":"crossref","DOI":"10.3310\/hta23170","article-title":"Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT","volume":"23","author":"Everitt","year":"2019","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.dld.2022.11.015_bib0216","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.cgh.2018.10.033","article-title":"Factors Associated With Efficacy of Cognitive Behavior Therapy vs Education for Patients With Irritable Bowel Syndrome","volume":"17","author":"Lackner","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.11.015_bib0217","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jpsychores.2018.07.003","article-title":"A randomized clinical trial of the Unified Protocol for Transdiagnostic treatment of emotional and gastrointestinal symptoms in patients with irritable bowel syndrome: evaluating efficacy and mechanism of change","volume":"113","author":"Mohsenabadi","year":"2018","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.dld.2022.11.015_bib0218","first-page":"176","article-title":"Comparing the Efficacy of Mindfulness-Based Stress Reduction Therapy with Emotion Regulation Treatment on Quality of Life and Symptoms of Irritable Bowel Syndrome","volume":"13","author":"Ghandi","year":"2018","journal-title":"Iran J Psychiatry"},{"key":"10.1016\/j.dld.2022.11.015_bib0219","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1037\/ccp0000483","article-title":"A randomized clinical trial of mindfulness-based cognitive therapy for women with irritable bowel syndrome-Effects and mechanisms","volume":"88","author":"Henrich","year":"2020","journal-title":"J Consult Clin Psychol"},{"key":"10.1016\/j.dld.2022.11.015_bib0220","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11126-019-09643-2","article-title":"Comparison of the Effect of Dialectical Behavior Therapy, Mindfulness Based Cognitive Therapy and Positive Psychotherapy on Perceived Stress and Quality of Life in Patients with Irritable Bowel Syndrome: a Pilot Randomized Controlled Trial","volume":"90","author":"Mohamadi","year":"2019","journal-title":"Psychiatr Q"},{"key":"10.1016\/j.dld.2022.11.015_bib0221","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(18)30310-8","article-title":"Efficacy of individual and group hypnotherapy in irritable bowel syndrome (IMAGINE): a multicentre randomised controlled trial","volume":"4","author":"Flik","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865822008143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865822008143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:21:31Z","timestamp":1761625291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865822008143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":221,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1590865822008143"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2022.11.015","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Italian guidelines for the management of irritable bowel syndrome","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2022.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}